Tivantinib, with the CAS number 1000873-98-2, is a small molecule inhibitor primarily known for its role in targeting the MET receptor tyrosine kinase. It is characterized by its ability to interfere with the signaling pathways associated with cell proliferation and survival, making it a subject of interest in cancer research, particularly for tumors that exhibit MET overexpression. Tivantinib is typically administered orally and has been investigated in clinical trials for various types of cancer, including non-small cell lung cancer and hepatocellular carcinoma. Its mechanism of action involves selective inhibition of MET, which can lead to reduced tumor growth and metastasis. The compound is often studied in combination with other therapeutic agents to enhance its efficacy. In terms of physical properties, Tivantinib is a crystalline solid with specific solubility characteristics that influence its bioavailability. As with many pharmaceutical compounds, its safety profile, potential side effects, and interactions with other drugs are critical considerations in its therapeutic application.

Tivantinib

1000873-98-2: (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione, ARQ 197, 2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-, (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione, Tivantinib

Please enquire for more information about Tivantinib including the price, delivery time and more detailed product information at the technical inquiry form on this page

CAS 1000873-98-2: Tivantinib

Tivantinib

Ref: 3D-AQB87398